99 related articles for article (PubMed ID: 26153878)
1. Digging for Buried Amino Acids Unearths New Protein Quality Control Treasure.
Jones RD; Gardner RG
Structure; 2015 Jul; 23(7):1151-2. PubMed ID: 26153878
[TBL] [Abstract][Full Text] [Related]
2. Structural Basis for Modulation of Quality Control Fate in a Marginally Stable Protein.
Brock KP; Abraham AC; Amen T; Kaganovich D; England JL
Structure; 2015 Jul; 23(7):1169-78. PubMed ID: 26027734
[TBL] [Abstract][Full Text] [Related]
3. Allosteric effects in the marginally stable von Hippel-Lindau tumor suppressor protein and allostery-based rescue mutant design.
Liu J; Nussinov R
Proc Natl Acad Sci U S A; 2008 Jan; 105(3):901-6. PubMed ID: 18195360
[TBL] [Abstract][Full Text] [Related]
4. Adding structural information to the von Hippel-Lindau (VHL) tumor suppressor interaction network.
Leonardi E; Murgia A; Tosatto SC
FEBS Lett; 2009 Nov; 583(22):3704-10. PubMed ID: 19878677
[TBL] [Abstract][Full Text] [Related]
5. Genotype-phenotype relations of the von Hippel-Lindau tumor suppressor inferred from a large-scale analysis of disease mutations and interactors.
Minervini G; Quaglia F; Tabaro F; Tosatto SCE
PLoS Comput Biol; 2019 Apr; 15(4):e1006478. PubMed ID: 30943211
[TBL] [Abstract][Full Text] [Related]
6. Homology modeling and molecular dynamics simulation of the HIF2α degradation-related HIF2α-VHL complex.
Dong X; Su X; Yu J; Liu J; Shi X; Pan Q; Yang J; Chen J; Li L; Cao H
J Mol Graph Model; 2017 Jan; 71():116-123. PubMed ID: 27902963
[TBL] [Abstract][Full Text] [Related]
7. VHL: Cullin-g the hypoxic response.
Kershaw NJ; Babon JJ
Structure; 2015 Mar; 23(3):435-436. PubMed ID: 25738382
[TBL] [Abstract][Full Text] [Related]
8. Isoform-specific interactions of the von Hippel-Lindau tumor suppressor protein.
Minervini G; Mazzotta GM; Masiero A; Sartori E; Corrà S; Potenza E; Costa R; Tosatto SC
Sci Rep; 2015 Jul; 5():12605. PubMed ID: 26211615
[TBL] [Abstract][Full Text] [Related]
9. The von Hippel-Lindau protein, HIF hydroxylation, and oxygen sensing.
Kaelin WG
Biochem Biophys Res Commun; 2005 Dec; 338(1):627-38. PubMed ID: 16153592
[TBL] [Abstract][Full Text] [Related]
10. Simulation of the mutation F76del on the von Hippel-Lindau tumor suppressor protein: mechanism of the disease and implications for drug development.
Limaverde-Sousa G; Barreto Ede A; Ferreira CG; Casali-da-Rocha JC
Proteins; 2013 Feb; 81(2):349-63. PubMed ID: 23011899
[TBL] [Abstract][Full Text] [Related]
11. Genotype-phenotype analysis of von Hippel-Lindau syndrome in Korean families: HIF-α binding site missense mutations elevate age-specific risk for CNS hemangioblastoma.
Lee JS; Lee JH; Lee KE; Kim JH; Hong JM; Ra EK; Seo SH; Lee SJ; Kim MJ; Park SS; Seong MW
BMC Med Genet; 2016 Jul; 17(1):48. PubMed ID: 27439424
[TBL] [Abstract][Full Text] [Related]
12. Chemical basis for the selectivity of the von Hippel Lindau tumor suppressor pVHL for prolyl-hydroxylated HIF-1alpha.
Illingworth CJ; Loenarz C; Schofield CJ; Domene C
Biochemistry; 2010 Aug; 49(32):6936-44. PubMed ID: 20695530
[TBL] [Abstract][Full Text] [Related]
13. Experimental and computational studies indicate specific binding of pVHL protein to Aurora-A kinase.
Ferchichi I; Stambouli N; Marrackchi R; Arlot Y; Prigent C; Fadiel A; Odunsi K; Ben Ammar Elgaaied A; Hamza A
J Phys Chem B; 2010 Jan; 114(3):1486-97. PubMed ID: 20047310
[TBL] [Abstract][Full Text] [Related]
14. Quantifying the Binding Interaction between the Hypoxia-Inducible Transcription Factor and the von Hippel-Lindau Suppressor.
Domene C; Jorgensen C; Vanommeslaeghe K; Schofield CJ; MacKerell A
J Chem Theory Comput; 2015 Aug; 11(8):3946-54. PubMed ID: 26574473
[TBL] [Abstract][Full Text] [Related]
15. Genetic characterization and protein stability analysis of a Chinese family with Von Hippel-Lindau disease.
Gao Y; Huang YP; Tu XA; Luo DS; Wang DH; Qiu SP; Xiang P; Li WQ; Jan R; Zhang YY; Sun XZ; Deng CH
Chin Med J (Engl); 2013; 126(19):3690-3. PubMed ID: 24112165
[TBL] [Abstract][Full Text] [Related]
16. von Hippel-Lindau β-domain-luciferase fusion protein as a bioluminescent hydroxyproline sensor for a hypoxia-inducible factor prolyl hydroxylase assay.
Hong S; Yum S; Ha NC; Jung Y
Anal Biochem; 2010 Dec; 407(2):220-5. PubMed ID: 20705044
[TBL] [Abstract][Full Text] [Related]
17. Beyond the hypoxia-inducible factor-centric tumour suppressor model of von Hippel-Lindau.
Roberts AM; Ohh M
Curr Opin Oncol; 2008 Jan; 20(1):83-9. PubMed ID: 18043261
[TBL] [Abstract][Full Text] [Related]
18. Cancer cells promote survival through depletion of the von Hippel-Lindau tumor suppressor by protein crosslinking.
Kim DS; Choi YB; Han BG; Park SY; Jeon Y; Kim DH; Ahn ER; Shin JE; Lee BI; Lee H; Hong KM; Kim SY
Oncogene; 2011 Dec; 30(48):4780-90. PubMed ID: 21625219
[TBL] [Abstract][Full Text] [Related]
19. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.
Zatyka M; da Silva NF; Clifford SC; Morris MR; Wiesener MS; Eckardt KU; Houlston RS; Richards FM; Latif F; Maher ER
Cancer Res; 2002 Jul; 62(13):3803-11. PubMed ID: 12097293
[TBL] [Abstract][Full Text] [Related]
20. Phosphorylation-dependent cleavage regulates von Hippel Lindau proteostasis and function.
German P; Bai S; Liu XD; Sun M; Zhou L; Kalra S; Zhang X; Minelli R; Scott KL; Mills GB; Jonasch E; Ding Z
Oncogene; 2016 Sep; 35(38):4973-80. PubMed ID: 26973240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
